Integrating Global Science & Education through Blockchain mHealth technologies, Informatics, Clinical Research, Lab Analytics
An in-vitro and in-vivo study published in the Journal of Investigative Dermatology in February 2015 found that treatment with delta-tetrahydrocannabinol and Cannabidiol helped to decrease the viability of melanoma cells.
Our founder and CEO is particularly motivated to bring the Company's research and product development to children suffering from DIPG, having been personally exposed to the challenge of a child and his family and the lack of treatment available to ease suffering. We know there is a significant opportunity to make a clinical impact in these situations merely by researching this alternative.
Additional Neuro Focus CTE in NFL, PTSD.
As research and Development evolve with merging medical markets, it is our desire to ensure we educate and increase awareness to the impact Cannabidiol Research can have and potentially deliver to future generations of children. We speak with many Clinicians and Researchers across the International Scientific Market and feel honored to be apart of this merging scientific research and data collection.
Sign up to receive CANNA HEALTHCARE Magazine, the ONLY interactive digital publication providing a multidisciplinary approach to medicinal Cannabidiol. Each issue highlights Abstracts, Clinical studies past and present, also including great articles and interviews with those in the clinical ecosystem.
2018-2019 Schedule updated monthly:
-January, 2018-LaClinica Steering Committee Meeting
-February 1-2, 2018 Denver, CO-WomenGrow Leadership Summit-Medical Panel Moderator
-February 15-16, 2018 Emerald Science Conference
-February 2018-Government Blockchain Association Working Group
-March 23-25, 2018 NECANN Convention
-April 12-14, 2018 World Medical Conference, Pittsburg PA
-April 26-28, 2018- ICR Conference University of Pueblo Colorado
-May 12-14, 2018 NECANN Convention
SUNESIS our mHealth application connects you to our HIPPA compliant cloud based server to critical analytical data and research. Cross dialog with other Clinicians researching DIPG and various Neutracuticals. We encourage volunteers to share and network with other Physicians, and Patients, to find a secure platform for your privacy and protection.
Patients interested in submitting for International Clinical Studies, will find updates on open studies. In addition to accepting Patient Reporting. Clinician and Patient Portal login launching Internationally early 2018.
To see that whatever a child may have to overcome, in his/her life, we want to ensure it is not their childhood.
-National Association of Professional Women
-Society of Cannabis Clinicians
-International Cannabinoid Research Society
-International Academy of Cannabinoid Medicine
-Americans For Same Access
-Los Angeles Market Leader/Chairwoman Women Grow
-La Clinica (Dr. Uma Dhanabalan)
-President California Chapter GBA (Government Blockchain Association) Chapter Chairwoman & Working Group - California
-Steering Committe Member, University of Colorado/La Clinica Dr. Uma Dhanabalan
(Q) Why research Neutracuticals for DIPG? (A) With no cure for this disease anything that shows promise to affecting this illness would be an improvement to what is not currently offered and effective. We want to give every Parent and Child a chance, to be apart of this critical research.
A unique investing opportunity awaits you and future generations. Email us today.
Monday - Friday: 9am - 5pm
11440 San Bernardo Court
San Diego, CA 92177